우울증 치료제 시장 : 약제 유형별, 적응증별, 유통 채널별, 지역별
Depression Therapeutics Market, By Drug Type, By Indication, By Distribution Channel, and By Geography
상품코드
:
1357959
리서치사
:
Coherent Market Insights
발행일
:
2023년 09월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 우울증 치료제 시장 규모는 2023년에 129억 달러로 추정되며, 예측 기간(2023-2030년) CAGR은 4.5%로 예측됩니다.
| 리포트 대상 범위 |
리포트 상세 |
| 기준년 |
2022년 |
2023년 시장 규모 |
129억 달러 |
| 실적 데이터 |
2018-2021년 |
예측 기간 |
2023-2030 |
| 예측 기간 CAGR |
4.50% |
2030년 시장 규모 예측 |
176억 달러 |
세계의 우울증 치료제 시장 점유율(%), 약물 유형별, 2023년
항우울제는 우울증의 증상을 완화하는 약물로, 다른 질병을 치료하는 데도 사용됩니다. 항우울제는 우울증 및 기타 정신건강 문제의 증상을 치료할 수 있습니다. 그러나 반드시 그 원인을 치료할 수 있는 것은 아닙니다. 의사는 종종 정신건강 문제의 원인을 해결하기 위해 대화 요법과 병행하여 항우울제를 처방합니다. 항우울제에는 여러 유형이 있습니다. 그들은 거의 동일한 뇌 화학 물질에 작용하고 비슷한 효과를 가져옵니다. 그러나 어떤 사람들은 어떤 유형의 항우울제가 다른 사람들보다 더 잘 작용합니다.
시장 역학
제약 산업의 주요 업체들은 다양한 임상시험 및 조사 활동을 수행하여 의약품 개발에 주력하고 있습니다. 따라서 시장 기업의 활발한 R&D 활동이 예측 기간 중 세계 우울증 치료제 시장의 성장을 가속할 것으로 예상됩니다. 예를 들어 2022년 11월, 중추신경계 질환을 앓고 있는 사람들의 희망 회복에 초점을 맞춘 생명공학 기업 오토반 테라퓨틱스(Autobahn Therapeutics)는 건강한 지원자를 대상으로 ABX-002의 1상 임상시험을 시작한다고 발표했습니다. 선택적 뇌 기능 개선 효과가 있는 갑상선 수용체 베타(TR-HY) 작용제이며, 오토반은 항우울제로 충분한 효과를 얻지 못하는 주요우울장애(MDD) 환자들을 위한 보조 치료제로서의 가능성을 검토하고 있습니다.
본시험의 주요 특징
- 세계의 우울증 치료제 시장을 상세 분석하고, 2022년을 기준년으로 한 예측 기간(2023-2030년)의 시장 규모 및 연평균 성장률(CAGR)을 제공합니다. 다양한 부문의 잠재적 매출 기회를 설명하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 시장 촉진요인, 억제요인, 기회, 신제품 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 주요 인사이트도 제공하고 있습니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터에 기반하여 세계의 우울증 치료제 시장의 주요 기업을 프로파일링하고 있습니다.
- 이 리포트로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 향후 제품 발매, 유형 업, 시장 확대, 마케팅 전술에 관한 정보에 기반한 의사결정을 시행할 수 있습니다.
- 세계의 우울증 치료제 시장 리포트는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참여업체, 재무 애널리스트 등 이 업계의 다양한 이해관계자에게 대응하고 있습니다.
- 이해관계자는 세계의 우울증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제
제2장 시장 전망
제3장 시장 역학, 규제, 동향 분석
- 촉진요인
- 억제요인
- 시장 기회
- 영향 분석
- 최근 신약 발매
- 역학
- 파이프라인 분석
- 유통 상황
- 합병, 인수 및 협업
- 규제 시나리오
- 주요 발전
- PEST 분석
제4장 세계의 우울증 치료제 시장 - 신종 코로나바이러스 감염증(COVID-19)의 영향 분석
- 경제적 영향
- 신종 코로나바이러스 감염증(COVID-19) 역학
- 수요와 공급에 대한 영향
제5장 세계의 우울증 치료제 시장 : 약제 유형별, 2018-2030년
- 항우울제
- 선택적 세로토닌 재흡수 저해제(SSRI)
- SNRI(Selective Norepinephrine Reuptake Inhibitors)
- 세로토닌 모듈레이터
- 삼환계 및 4환계 항우울제
- 비정형 항우울제
- 항정신병약
- 기타
제6장 세계의 우울증 치료제 시장 : 적응증별, 2018-2030년
- 주요우울장애(MDD)
- 조울증
- 기분 변조성 장애
- 산후 우울증
- SAD(Seasonal Affective Disorder)
- 월경전불쾌장애(PMDD)
- 기타
제7장 세계의 우울증 치료제 시장 : 유통 채널별, 2018-2030년
제8장 세계의 우울증 치료제 시장 : 지역별, 2018-2030년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- 기업 개요
- Johnson & Johnson
- GlaxoSmithKline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Eli Lilly and Company
- Pfizer, Inc.
- Allergan plc.
- H. Lundbeck A/S
- Alkermes
- Allergan
- Novartis AG
- Biogen
- Sage Therapeutics, Inc.
- AbbVie Inc.
제10장 섹션
KSA
영문 목차
The global depression therapeutics market is estimated to be valued at US$ 12.9 billion in 2023 and is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).
| Report Coverage |
Report Details |
| Base Year: |
2022 |
Market Size in 2023: |
US$ 12.9 Bn |
| Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: |
4.50% |
2030 Value Projection: |
US$ 17.6 Bn |
Global Depression Therapeutics Market Share (%), By Drug Type, 2023
Depression therapeutics are medications that can help relieve the symptoms of depression and are also used in the treatment of some other conditions. Antidepressants can treat the symptoms of depression or other mental health problems. But they don't always deal with the causes. Doctors will often prescribe them alongside talking therapy, to help deal with the causes of mental health problems. There are several different types of antidepressants. They mostly affect the same brain chemicals and cause similar effects. But some people may respond to certain antidepressants better than others.
The different types are:
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
- Tricyclics and tricyclic-related drugs
- Monoamine Oxidase Inhibitors (MAOIs)
- Others
Market Dynamics
The key players in the pharmaceutical industry are focusing on the development of drugs by conducting various clinical trials and research operations. Thus, increasing research and development activities by market players are expected to drive the growth of the global depression therapeutics market over the forecast period. For instance, in November 2022, Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, announced the initiation of dosing in the company's Phase 1 clinical trial of ABX-002 in healthy volunteers. ABX-002 is a potent and selective brain-boosting thyroid receptor beta (TRβ) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.
Key features of the study:
- This report provides an in-depth analysis of the global depression therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global depression therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Johnson & Johnson, GlaxoSmithKline plc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Eli Lilly and Company, Sanofi S.A., Pfizer, Inc., Allergan plc., H. Lundbeck A/S, Alkermes, Allergan, Novartis AG, Biogen, Sage Therapeutics, Inc., and AbbVie Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global depression therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression therapeutics market.
Detailed Segmentation:
- Global Depression Therapeutics Market, By Drug Type:
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antidepressants
- Antipsychotics
- Others
- Global Depression Therapeutics Market, By Indication:
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- Global Depression Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Depression Therapeutics Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Johnson & JohnsonGlaxoSmithKline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Eli Lilly and Company
- Sanofi S.A.
- Pfizer, Inc.
- Allergan plc.
- H. Lundbeck A/S
- Alkermes
- Allergan
- Novartis AG
- Biogen
- Sage Therapeutics, Inc.
- AbbVie Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Pipeline Analysis
- Distribution Landscape
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Depression Therapeutics Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Depression Therapeutics Market, By Drug Type, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
6. Global Depression Therapeutics Market, By Indication, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
7. Global Depression Therapeutics Market, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
8. Global Depression Therapeutics Market, By Region, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018 -2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Eli Lilly and Company
- Pfizer, Inc.
- Allergan plc.
- H. Lundbeck A/S
- Alkermes
- Allergan
- Novartis AG
- Biogen
- Sage Therapeutics, Inc.
- AbbVie Inc.
10. Section
- References
- Research Methodology
- About us and Sales Contact
관련자료
